SAGE News and Press, Sage Therapeutics Inc. From 05/28/24

2024-05-28 18:00:05 ET Joel Beatty from Robert W. Baird issued a price target of $15.00 for SAGE on 2024-05-28 16:15:00. The adjusted price target was set to $15.00. At the time of the announcement, SAGE was trading at $11.93. The overall price target consensus is at $49...

2024-05-13 21:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY) ...

2024-04-29 09:00:00 ET Summary Biogen Inc.'s Q1 earnings missed estimates with a decrease in revenue; however, EPS showed minor improvements. Operational cost reductions contributed to the EPS gain despite revenue shortfall, with significant cuts in R&D spending. Skyclarys...

2024-04-25 14:17:02 ET Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Conference Call April 25, 2024 08:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board...

Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...

2024-04-25 06:34:32 ET More on Sage Therapeutics Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade) SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation...

Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024 ...

2024-04-24 13:45:23 ET More on Sage Therapeutics Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade) SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation...

2024-04-24 09:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...